Pustular dermatosis of the scalp due to topical minoxidil 5%

Topical minoxidil, the only approved treatment for female pattern hair loss (FPHL), has been associated with scalp allergic contact dermatitis (ACD). We report the case of a female patient who developed ACD from minoxidil solution. A 30-year-old women presented with pruriginous and pustular lesions...

Full description

Bibliographic Details
Main Authors: Ouiam El Anzi, Badreddine Hassam
Format: Article
Language:English
Published: The Pan African Medical Journal 2018-05-01
Series:The Pan African Medical Journal
Subjects:
Online Access: https://www.panafrican-med-journal.com/content/article/30/83/pdf/83.pdf
_version_ 1818977969190731776
author Ouiam El Anzi
Badreddine Hassam
author_facet Ouiam El Anzi
Badreddine Hassam
author_sort Ouiam El Anzi
collection DOAJ
description Topical minoxidil, the only approved treatment for female pattern hair loss (FPHL), has been associated with scalp allergic contact dermatitis (ACD). We report the case of a female patient who developed ACD from minoxidil solution. A 30-year-old women presented with pruriginous and pustular lesions over an erythematous area on the scalp and forehead. These lesions had appeared after 1 week of treatment with 5% minoxidil solution (Foligan�)[minoxidil 5%, ethanol, propylene glycol and purified water], for androgenetic alopecia. Physical examination revealed multiple millimetric papulovesicles and papulopustules over an erythematous oedematous area on the frontal scalp and forehead. The patient refused to have a biopsy taken. With these clinical lesions a diagnosis of pustular contact dermatitis was made. Minoxidil solution was stopped and topical corticosteroid therapy twice a day was started. A complete clearance of the lesions could be observed after 5 days. Topical 2,6-diamino-4-piperidinopyrimidine 1-oxide (minoxidil) has been shown to be effective in the treatment of androgenetic alopecia for over 15 years. Minoxidil 5% solution has a favorable safety profile, with adverse effects limited to the site of application (5.7% of patients) and signed by pruritus, erythema, scaling and dryness. The most common causes of these symptoms include irritant contact dermatitis, allergic contact dermatitis, or exacerbation of seborrheic dermatitis. Although cases of pustular allergic contact dermatitis have been anecdotally reported. We conclude that our case is interesting in that it represents an uncommon reaction to a drug used very frequently in dermatology.
first_indexed 2024-12-20T16:36:11Z
format Article
id doaj.art-b45f3c278f5d4158a8fd8fc7c7e556b3
institution Directory Open Access Journal
issn 1937-8688
1937-8688
language English
last_indexed 2024-12-20T16:36:11Z
publishDate 2018-05-01
publisher The Pan African Medical Journal
record_format Article
series The Pan African Medical Journal
spelling doaj.art-b45f3c278f5d4158a8fd8fc7c7e556b32022-12-21T19:33:08ZengThe Pan African Medical JournalThe Pan African Medical Journal1937-86881937-86882018-05-01308310.11604/pamj.2018.30.83.1538415384Pustular dermatosis of the scalp due to topical minoxidil 5%Ouiam El Anzi0Badreddine Hassam1 Service de Dermatologie et Vénérologie, Centre Hospitalier Universitaire Ibn Sina, Faculté de Médecine et de Pharmacie, Université Mohammed V, Rabat, Maroc Service de Dermatologie et Vénérologie, Centre Hospitalier Universitaire Ibn Sina, Faculté de Médecine et de Pharmacie, Université Mohammed V, Rabat, Maroc Topical minoxidil, the only approved treatment for female pattern hair loss (FPHL), has been associated with scalp allergic contact dermatitis (ACD). We report the case of a female patient who developed ACD from minoxidil solution. A 30-year-old women presented with pruriginous and pustular lesions over an erythematous area on the scalp and forehead. These lesions had appeared after 1 week of treatment with 5% minoxidil solution (Foligan�)[minoxidil 5%, ethanol, propylene glycol and purified water], for androgenetic alopecia. Physical examination revealed multiple millimetric papulovesicles and papulopustules over an erythematous oedematous area on the frontal scalp and forehead. The patient refused to have a biopsy taken. With these clinical lesions a diagnosis of pustular contact dermatitis was made. Minoxidil solution was stopped and topical corticosteroid therapy twice a day was started. A complete clearance of the lesions could be observed after 5 days. Topical 2,6-diamino-4-piperidinopyrimidine 1-oxide (minoxidil) has been shown to be effective in the treatment of androgenetic alopecia for over 15 years. Minoxidil 5% solution has a favorable safety profile, with adverse effects limited to the site of application (5.7% of patients) and signed by pruritus, erythema, scaling and dryness. The most common causes of these symptoms include irritant contact dermatitis, allergic contact dermatitis, or exacerbation of seborrheic dermatitis. Although cases of pustular allergic contact dermatitis have been anecdotally reported. We conclude that our case is interesting in that it represents an uncommon reaction to a drug used very frequently in dermatology. https://www.panafrican-med-journal.com/content/article/30/83/pdf/83.pdf minoxidilallergic contact dermatitispustules
spellingShingle Ouiam El Anzi
Badreddine Hassam
Pustular dermatosis of the scalp due to topical minoxidil 5%
The Pan African Medical Journal
minoxidil
allergic contact dermatitis
pustules
title Pustular dermatosis of the scalp due to topical minoxidil 5%
title_full Pustular dermatosis of the scalp due to topical minoxidil 5%
title_fullStr Pustular dermatosis of the scalp due to topical minoxidil 5%
title_full_unstemmed Pustular dermatosis of the scalp due to topical minoxidil 5%
title_short Pustular dermatosis of the scalp due to topical minoxidil 5%
title_sort pustular dermatosis of the scalp due to topical minoxidil 5
topic minoxidil
allergic contact dermatitis
pustules
url https://www.panafrican-med-journal.com/content/article/30/83/pdf/83.pdf
work_keys_str_mv AT ouiamelanzi pustulardermatosisofthescalpduetotopicalminoxidil5
AT badreddinehassam pustulardermatosisofthescalpduetotopicalminoxidil5